Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Financial Statements
- Click here to download Gilead Sciences, Inc.'s Income Statement
- Click here to download Gilead Sciences, Inc.'s Balance Sheet
- Click here to download Gilead Sciences, Inc.'s Statement of Cash Flows
Key Info
- Industry: Biological Product (except Diagnostic) Manufacturing
- Sector: Manufacturing
- CEO Name: Daniel O'Day
Key Statistics
- Stock Price: $73.25
- Dividend Yield: 4.0%
- Market Capitalization: $91,201,906,292
- Shares Outstanding: 1,245,077,219
- Number of Employees: 17,000
- Trailing 12-Month EPS: $4.5
- Trailing 12-Month DPS: $2.93
- Payout Ratio: 65.10000000000001%
Important Dates
- Next Earnings Date: 2024-04-25
- Next Ex-Dividend Date: 2024-03-14
Price Trends
- Current Stock Price: $73.25
- 52-week high: $86.09
- 52-week low: $69.12
- 200-day moving average: $75.15
- 50-day moving average: $72.31
Performance
- 1-Month Price Return: 2.8%
- 3-Month Price Return: -7.7%
- 6-Month Price Return: 1.6%
- 1-Year Price Return: -2.8%
- 2-Year Price Return: 38.2%
- 5-Year Price Return: 43.4%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast